NEW YORK – Roche subsidiary Foundation Medicine announced Tuesday that it has received a five-year contract from the US Department of Veterans Affairs to provide tumor molecular profiling tests to veterans with cancer.
The contract is part of the VA's National Precision Oncology Program and covers the tissue-based FoundationOne CDx assay, liquid-based FoundationOne Liquid CDx test, tissue-based RNA sequencing FoundationOne RNA assay, and FoundationOne Heme for hematologic malignancies.
The new national contract is the second consecutive contract awarded to Foundation from the VA. The first was awarded in 2019 for $111.5 million and covered FoundationOne CDx, FoundationOne Liquid CDx, and FoundationOne Heme.
"We are honored to continue our relationship with the VA’s National Precision Oncology Program to provide veterans with high-quality diagnostic testing," Foundation Chief Commercial Officer Annie Murphy said in a statement. "Our comprehensive portfolio of tissue and blood-based tests can simplify complex decisions by generating quality information to enable better decision-making, patient outcomes, and treatment options."
Financial and other terms of the contract were not disclosed.